- Home
- PSNL vs ADRX Comparison
PSNL vs ADRX Comparison
Compare PSNL & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ADRX |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2019 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ADRX |
|---|---|---|
| Price | $15.72 | $14.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.17 | ★ $34.25 |
| AVG Volume (30 Days) | ★ 2.1M | 396.7K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $27.28 | $89.41 |
| Revenue Next Year | $24.60 | $510.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.96 | $12.50 |
| 52 Week High | $18.89 | $19.57 |
Technical Indicators
Market Signals| Indicator | PSNL | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 39.02 |
| Support Level | $15.51 | $12.50 |
| Resistance Level | $16.49 | $18.94 |
| Average True Range (ATR) | 0.24 | 1.59 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 31.97 | 30.24 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.